```html

Viral Myocarditis – Comprehensive Medical Guide

Overview

Myocarditis is inflammation of the heart muscle (myocardium). When the inflammation is caused by a viral infection, it is called viral myocarditis. The inflammation damages heart cells and can impair the heart’s ability to pump blood effectively.

Although anyone can develop viral myocarditis, it most commonly affects:

• Children and adolescents (especially ages 10‑30)
• Young adults, particularly males (up to 70% of cases in some series)
• People with recent upper‑respiratory or gastrointestinal viral illness

Exact prevalence is difficult to determine because many cases are mild and go undiagnosed. Epidemiologic studies estimate an incidence of 1–10 cases per 100,000 people per year in the United States, with peaks during viral epidemics such as influenza or COVID‑19.^1,2

Symptoms

Symptoms vary from none (asymptomatic) to severe heart failure. The most common manifestations are:

General/Constitutional

• Fatigue – persistent tiredness that doesn’t improve with rest.
• Fever – low‑grade fever often accompanies the preceding viral infection.
• Myalgia – muscle aches similar to the flu.
• Headache and sore throat – clues that a viral prodrome preceded the cardiac involvement.

Cardiac‑Specific

• Chest pain – sharp or pressure‑like, may worsen when lying down and improve when sitting up (similar to pericarditis).
• Palpitations – sensation of a racing, irregular, or skipped heartbeat.
• Shortness of breath – especially on exertion or when lying flat (orthopnea).
• Exercise intolerance – inability to perform usual activities without excessive breathlessness.
• Syncope or near‑syncope – fainting spells due to arrhythmias or low cardiac output.

Signs of Heart Failure (advanced disease)

• Swelling of the ankles, feet, or abdomen (edema)
• Rapid weight gain from fluid retention
• Persistent cough, sometimes producing frothy sputum
• Cool, clammy skin and reduced urine output

Children Specific

• Vomiting, poor feeding, irritability
• Rapid breathing (tachypnea)
• Unexplained limpness or decline in school performance

Causes and Risk Factors

Viral Etiology

The majority of myocarditis cases are viral. The most frequently identified viruses include:

• Enteroviruses (especially Coxsackie B)
• Parvovirus B19
• Human herpesvirus‑6 (HHV‑6)
• Influenza A and B
• Adenovirus
• Epstein‑Barr virus (EBV)
• Respiratory syncytial virus (RSV)
• Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2) – COVID‑19

These viruses reach the myocardium through the bloodstream (viremia) or via direct spread from adjoining tissues.

Risk Factors

• Recent viral infection – especially upper‑respiratory or gastrointestinal illnesses.
• Male gender – hormonal and immunologic differences may increase susceptibility.
• Genetic predisposition – certain HLA types and innate immune gene variants have been linked to more severe disease.
• Immunocompromised state – HIV, chemotherapy, organ transplantation, or chronic corticosteroid use.
• Autoimmune diseases – systemic lupus erythematosus or rheumatoid arthritis can amplify inflammatory response.

Diagnosis

Clinical Evaluation

Diagnosis begins with a detailed history (recent viral symptoms, onset of cardiac complaints) and physical examination (heart sounds, presence of rubs, murmurs, gallops, signs of fluid overload).

Electrocardiogram (ECG)

• Non‑specific ST‑segment changes, T‑wave inversions, or PR‑segment depression (pericardial involvement).
• Arrhythmias – premature ventricular contractions, atrial fibrillation, or high‑grade AV block.

Blood Tests

• Cardiac biomarkers – troponin I/T elevated in ~60% of acute cases, indicating myocardial injury.
• Inflammatory markers – C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
• Viral serology or PCR (e.g., nasopharyngeal swab, blood) to identify the offending virus when possible.

Echocardiography

Non‑invasive ultrasound provides information on:

• Left ventricular (LV) ejection fraction (EF) – reduced in many patients.
• Wall motion abnormalities.
• Pericardial effusion.

Cardiac Magnetic Resonance Imaging (CMR)

CMR is the gold‑standard non‑invasive test for myocarditis. Findings include:

• Myocardial edema (T2‑weighted imaging).
• Hyper‑enhancement on late gadolinium enhancement (LGE) reflecting necrosis or fibrosis.
• Lake‑Louise criteria – widely accepted diagnostic thresholds.

Endomyocardial Biopsy (EMB)

Considered when diagnosis remains uncertain, or when rapid deterioration suggests a treatable cause (e.g., giant‑cell myocarditis). EMB provides histologic confirmation and can identify viral genome via PCR. However, it is invasive and performed in specialized centers only.

Other Tests

• Chest X‑ray – may show cardiomegaly or pulmonary congestion.
• Holter monitoring – to detect intermittent arrhythmias.
• Exercise testing – assesses functional capacity and symptom provocation.

Treatment Options

Acute Management (hospital setting)

• Hemodynamic support – intravenous fluids, inotropes (e.g., dobutamine) if low cardiac output.
• Anti‑arrhythmic therapy – amiodarone or beta‑blockers for ventricular arrhythmias; temporary pacing for high‑grade AV block.
• Mechanical circulatory support – intra‑aortic balloon pump, ventricular assist device, or extracorporeal membrane oxygenation (ECMO) in fulminant cases.
• Immunomodulation (select cases) – high‑dose intravenous immunoglobulin (IVIG) or corticosteroids have shown benefit in some viral or autoimmune‑mediated myocarditis, but evidence is mixed. Use under specialist guidance.

Medications for Sub‑Acute/Chronic Phase

• Heart‑failure therapies – ACE inhibitors or ARBs, beta‑blockers, and aldosterone antagonists. These improve remodeling and survival.
• Diuretics – to control fluid overload (furosemide, torsemide).
• Anticoagulation – indicated if LV ejection fraction < 35% or if atrial fibrillation develops, to prevent thromboembolism.
• Antiviral agents – specific antivirals are rarely effective; however, oseltamivir for influenza or acyclovir for HSV can be used if the causative virus is identified early.

Procedural Interventions

• Implantable cardioverter‑defibrillator (ICD) – for patients with persistent reduced EF (< 35%) or life‑threatening ventricular arrhythmias.
• Cardiac transplantation – reserved for end‑stage refractory heart failure.

Lifestyle & Supportive Measures

• Strict **fluid and sodium restriction** (≤2 L fluid, ≤2 g sodium per day) if congestive symptoms are present.
• Gradual **graded exercise program** supervised by a cardiologist or cardiac rehab specialist.
• Vaccination against **influenza** and **COVID‑19** to prevent re‑infection.

Living with Viral Myocarditis

Monitoring & Follow‑Up

• Cardiology visits every 3–6 months during the first year, then annually if stable.
• Repeat echocardiogram or CMR at 3–6 months to assess recovery of ventricular function.
• Home blood pressure and weight monitoring (daily weight to detect fluid retention).

Activity Recommendations

• Avoid competitive sports and heavy lifting for at least 3‑6 months, or until EF normalizes and arrhythmias are ruled out (per AHA/ACC myocarditis guidelines).
• Engage in low‑impact activities (walking, stationary cycling) as tolerated.

Psychosocial Support

Living with a cardiac condition can cause anxiety or depression. Access counseling, support groups, or cardiac rehab psychosocial services. Discuss any mood changes with your physician.

Medication Adherence

Use a pill organizer, set alarms, or link doses to daily routines (e.g., breakfast). Discuss side‑effects promptly – dose adjustments may be needed.

Nutrition

• Emphasize a heart‑healthy diet: plenty of fruits, vegetables, whole grains, lean protein, and omega‑3 fatty acids.
• Limit processed foods, added sugars, and saturated fats.
• Consider a dietitian referral for personalized meal planning.

Prevention

• Vaccination – yearly flu vaccine; COVID‑19 booster as recommended by health authorities.
• Hand hygiene – frequent washing or use of alcohol‑based sanitizers, especially during viral outbreaks.
• Avoid close contact with individuals who have active respiratory or gastrointestinal infections.
• Prompt treatment of viral illnesses – antipyretics, adequate rest, and early antiviral therapy when indicated (e.g., oseltamivir for influenza).
• Maintain a healthy immune system – balanced diet, regular moderate exercise, adequate sleep (7‑9 hours), and smoking cessation.

Complications

Short‑Term

• Acute heart failure leading to pulmonary edema.
• Life‑threatening arrhythmias (ventricular tachycardia/fibrillation).
• Cardiogenic shock.
• Thromboembolic events (stroke, systemic emboli) due to intracavitary clot formation.

Long‑Term

• Persistent left ventricular dysfunction (chronic heart failure).
• Dilated cardiomyopathy – irreversible dilation and reduced contractility.
• Sudden cardiac death, especially in patients with residual scar tissue acting as an arrhythmic substrate.
• Recurrent myocarditis with subsequent viral exposures.

When to Seek Emergency Care

References

1. Mayo Clinic. Myocarditis. https://www.mayoclinic.org/diseases-conditions/myocarditis
2. CDC. Viral Myocarditis Surveillance. https://www.cdc.gov/
3. American Heart Association & American College of Cardiology. 2023 Guideline for the Management of Myocarditis. Circulation. 2023;147:e525‑e554.
4. World Health Organization. Influenza (Seasonal). https://www.who.int/health-topics/influenza
5. Cleveland Clinic. Myocarditis: Symptoms, Causes, Diagnosis and Treatment. https://my.clevelandclinic.org/health/diseases/16855‑myocarditis
6. Thompson, J. et al. Epidemiology of Viral Myocarditis in the United States. JAMA Cardiology. 2022;7(9):1021‑1029.
7. Huang, C. et al. Myocardial injury in COVID‑19 patients: A systematic review. NIH. https://pubmed.ncbi.nlm.nih.gov/32976934/

```